Skip to main content
. 2022 Jan 4;98(1):e40–e50. doi: 10.1212/WNL.0000000000012952

Figure 4. Changes From Baseline in UPDRS III Scores.

Figure 4

(A) “Off” medication. (B) “On” medication. Data shown are mean change in points ± SEM. Unified Parkinson's Disease Rating Scale (UPDRS) III “off”-medication scores improved in all cohorts throughout the trial, and “on”-medication scores improved in cohorts 2 and 3 throughout the trial. A sensitivity analysis that excluded the participant in cohort 1 who underwent deep brain stimulation resulted in a mean ± SEM change from baseline of −17.3 ± 4.5 points (“off” medication) and 0.8 ± 2.4 points (“on” medication) at month 36.